Evidence map›Paper›PMID 36145668›Full record

ReviewPharmaceutics2022

"Targeting Design" of Nanoparticles in Tumor Therapy.

Tingting Yang, Jingming Zhai, Dong Hu, Ruyue Yang, Guidan Wang, Yuanpei Li, Gaofeng Liang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Lysosome-Targeted Bifunctional Therapeutics Induce Autodynamic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tingting YangSchool of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.
Jingming ZhaiDepartment of General Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science & Technology, Luoyang 471003, China.
Dong HuSchool of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.
Ruyue YangSchool of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.
Guidan WangSchool of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.
Yuanpei LiSchool of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.
Gaofeng LiangSchool of Basic Medical Sciences, Henan University of Science & Technology, Luoyang 471023, China.

Funding

Innovation Scientists and Technicians Troop Construction Projects of Henan Province CXTD2017071National Natural Science Foundation of China U1804193
6 · The paper itself

Abstract

Tumor-targeted therapy based on nanoparticles is a popular research direction in the biomedical field. After decades of research and development, both the passive targeting ability of the inherent properties of NPs and the active targeting based on ligand receptor interaction have gained deeper understanding. Unfortunately, most targeted delivery strategies are still in the preclinical trial stage, so it is necessary to further study the biological fate of particles in vivo and the interaction mechanism with tumors. This article reviews different targeted delivery strategies based on NPs, and focuses on the physical and chemical properties of NPs (size, morphology, surface and intrinsic properties), ligands (binding number/force, activity and species) and receptors (endocytosis, distribution and recycling) and other factors that affect particle targeting. The limitations and solutions of these factors are further discussed, and a variety of new targeting schemes are introduced, hoping to provide guidance for future targeting design and achieve the purpose of rapid transformation of targeted particles into clinical application.

Indexed as

applicationcancer therapydrug deliverynanoparticlestargeted transportation

Identifiers

PMID36145668
PMCPMC9501451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.